<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103554</url>
  </required_header>
  <id_info>
    <org_study_id>ENVAD-HF</org_study_id>
    <nct_id>NCT04103554</nct_id>
  </id_info>
  <brief_title>Sacubitril/Valsartan in Left Ventricular Assist Device Recipients</brief_title>
  <acronym>ENVAD-HF</acronym>
  <official_title>A Multicenter, Randomized, Open-label, Parallel Group, Pilot Study to Evaluate the Use of Sacubitril/Valsartan in HeartMate 3 LVAD Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zagreb</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zagreb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability of&#xD;
      sacubitril/valsartan compared with standard of care used for treating BP in patients that&#xD;
      have been implanted with the Heart Mate 3 LVAD (events of special interest - all cause death,&#xD;
      right ventricular failure, bleeding events, deterioration in renal function, hyperkalemia,&#xD;
      symptomatic hypotension).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from all-cause death, deterioration in renal function (reaching end-stage renal disease (ESRD), renal death or 50% decline in eGFR), hyperkalemia or symptomatic hypotension</measure>
    <time_frame>3 months</time_frame>
    <description>End-stage renal disease defined as one of the following:&#xD;
Initiation of dialysis (e.g., hemodialysis, peritoneal dialysis, or continuous venovenous hemodialysis), continuing for ≥ 20 days without known recovery of renal function&#xD;
Initiation of dialysis with death before 30 days (excludes dialysis events associated with acute kidney injury with death before 30 days)&#xD;
A drop in eGFR from baseline (randomization, i.e. Visit 101) to a value &lt;15 mL/min/1.73m2 on two consecutive measurements separated by≥ 20 days&#xD;
Occurrence of kidney transplantation&#xD;
50% sustained decline in eGFR: 50% decline from baseline (Randomization, Visit 101) as determined by 2 consecutive post-baseline measurements separated by ≥ 20 days&#xD;
Hyperkalemia: serum potassium ≥6.0 mmol/L [mEq/L]) Hypotension: symptomatic reduction in blood pressure requiring withdrawal of study medication or any BP lowering medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP from enrolment to 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Burden of hemocompatibility (hemocompatibility score)</measure>
    <time_frame>3 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RV failure events</measure>
    <time_frame>3 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first unplanned hospitalisation</measure>
    <time_frame>3 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unplanned hospitalizations</measure>
    <time_frame>3 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood-pressure lowering medications</measure>
    <time_frame>3 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR values</measure>
    <time_frame>3 months, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>sacubitril/valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care for treating blood pressure per center protocols</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril-Valsartan</intervention_name>
    <description>Sacubitril-Valsartan 24/26 mg BID, 49/51 mg BID, 97/103 mg BID</description>
    <arm_group_label>sacubitril/valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>standard of care used for treating BP</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent must be obtained before any assessment is performed.&#xD;
&#xD;
          2. ≥18 years of age, male or female&#xD;
&#xD;
          3. Recently implanted HeartMate 3 LVAD recipients, in stable condition and deemed ready&#xD;
             for discharge or chronic, stable, ambulatory HeartMate 3 LVAD carriers implanted&#xD;
             within 1 year prior to enrolment&#xD;
&#xD;
        1. Current acute decompensated HF (including right ventricular failure) requiring therapy&#xD;
        with intravenous diuretics or vasodilators and/or inotropic drugs within the past 48 hours&#xD;
        2. History of hypersensitivity to sacubitril/valsartan or to drugs of similar chemical&#xD;
        classes, patients with a known history of angioedema 3. Patients with mean blood pressure&#xD;
        ≤75 mmHg (systolic blood pressure i.e. Doppler opening blood pressure ≤90 mmHg in those&#xD;
        pulsatile and measured by Doppler method) or symptomatic hypotension 4. eGFR &lt; 30&#xD;
        mL/min/1.73m2 as calculated by the Modification in Diet in Renal Disease (MDRD) formula at&#xD;
        Visit 1 5. Patients with serum potassium &gt;5.4 mmol/L (mEq/L) at Visit 1 6. Hemodynamically&#xD;
        unstable patients or those with ongoing MCS other than LVAD or those with planned&#xD;
        biventricular support 7. Hemodynamically significant aortic insufficiency in the opinion of&#xD;
        the investigator 8. Irreversible end-organ dysfunction 9. Previous sacubitril/valsartan use&#xD;
        while on LVAD support 10. Acute coronary syndrome, stroke, transient ischemic attack,&#xD;
        cardiac, carotid or other major CV surgery, percutaneous coronary intervention (PCI) or&#xD;
        carotid angioplasty within 30 days prior to enrolment 11. Life-threatening or uncontrolled&#xD;
        dysrhythmia, including symptomatic or sustained ventricular tachycardia and atrial&#xD;
        fibrillation or flutter with a resting ventricular rate &gt;110 bpm at enrolment 12. Any&#xD;
        surgical or medical condition, which in the opinion of the Investigator, may place the&#xD;
        patient at higher risk from his/her participation in the study, or is likely to prevent the&#xD;
        patient from complying with the requirements of the study or completing the study 13.&#xD;
        Active infection with hemodynamic compromise 14. hemoglobin (Hgb) &lt;8 g/dl 15. body mass&#xD;
        index (BMI) &gt; 45 kg/m2 16. Congenital heart disease 17. Coronary or carotid artery disease&#xD;
        or valvular heart disease likely to require surgical or percutaneous intervention within&#xD;
        the 6 months after enrolment 18. Evidence of hepatic disease as determined by any one of&#xD;
        the following: SGOT (AST) or SGPT (ALT) values exceeding 3x ULN, bilirubin &gt;1.5 mg/dl at&#xD;
        Visit 1 19. Pregnant or nursing (lactating) women and women of child-bearing potential&#xD;
        unless they are using highly effective methods of contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maja Cikes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zagreb School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Filip Puskaric, MD</last_name>
    <phone>385997505240</phone>
    <email>filip.puskaric@mef.hr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Jakush, MD</last_name>
      <phone>+385915605795</phone>
      <email>nina.jakush@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maja Cikes, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zagreb</investigator_affiliation>
    <investigator_full_name>Maja Cikes</investigator_full_name>
    <investigator_title>Associate professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>LVAD (Left Ventricular Assist Device)</keyword>
  <keyword>sacubitril/valsartan</keyword>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

